4.6 Article

Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report

期刊

INFECTION AND DRUG RESISTANCE
卷 16, 期 -, 页码 2467-2473

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/IDR.S384035

关键词

hemophagocytic lymphohistiocytosis; COVID-19; ruxolitinib; case report

向作者/读者索取更多资源

This case study reports the diagnosis and successful treatment of an older male patient with HLH related to previous SARS-CoV-2 infection. Fever was the initial clinical manifestation, but deterioration in clinical condition and laboratory parameters was observed. The patient responded poorly to classical therapy, but showed improvement after treatment with ruxolitinib.
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. SARS-CoV-2 infection can induce secondary HLH, as described in previous case reports, but diagnosis and treatment are challenging.Case Study: We described an older male patient diagnosed with HLH related to previous SARS-CoV-2 infection. Fever was the only clinical manifestation initially but deterioration in clinical condition and laboratory parameters was observed during hospitalization. He responded poorly to classical therapy but was successfully treated with ruxolitinib.Conclusion: Clinicians should be aware of the possibility of HLH secondary to mild SARS-CoV-2 infection and take timely ther-apeutic measures to inhibit an inflammatory factor storm. Ruxolitinib is a potential choice for COVID-19 related HLH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据